We summarized the incidence of major adverse cardiovascular events(MACE) and hypertension associated with the use of CDK4/6 inhibitor in randomizedcontrol trials (RCTs) and compared the risks of MACE and hypertension throughnetwork-meta analysis (NMA). Here, CDK4 is linked to Hypertension.